Article
Biochemistry & Molecular Biology
Anastasios Gkountakos, Giovanni Centonze, Emanuele Vita, Lorenzo Belluomini, Michele Milella, Emilio Bria, Massimo Milione, Aldo Scarpa, Michele Simbolo
Summary: The use of EGFR tyrosine kinase inhibitors has significantly improved the management of lung adenocarcinoma, but long-term clinical benefit is compromised by multiple resistance mechanisms, including metabolic remodeling. Metabolic pathways and metabolites have been implicated in resistance to EGFR TKIs and they may also serve as predictive biomarkers. Additionally, targeting nutrient dependencies may offer a potential strategy to counteract resistance.
Article
Oncology
Lingling Zhao, Zhen Wang, Haiwei Du, Songan Chen, Pingli Wang
Summary: The efficacy of EGFR-TKIs in patients with rare EGFR mutations such as EGFR-KDD remains unclear, although case reports have shown variable antitumor responses. Treatment with afatinib in a 61-year-old male with T1N3M0 LUAD harboring EGFR-KDD resulted in partial response with a progression-free survival of 12 months and counting, providing clinical evidence for EGFR-TKI administration in advanced LUAD patients with EGFR-KDD.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Gee-Chen Chang
Summary: This study aimed to investigate the efficacy of different EGFR-TKIs plus bevacizumab in advanced EGFR-mutant lung adenocarcinoma patients. The results showed that both erlotinib plus bevacizumab and afatinib plus bevacizumab as first-line treatment provided solid clinical efficacy in advanced EGFR-mutant lung adenocarcinoma patients.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Ming-Ju Tsai, Jen-Yu Hung, Juei-Yang Ma, Yu-Chen Tsai, Kuan-Li Wu, Mei-Hsuan Lee, Chia-Yu Kuo, Cheng-Hao Chuang, Tai-Huang Lee, Yen-Lung Lee, Chun-Ming Huang, Mei-Chiou Shen, Chih-Jen Yang, Inn-Wen Chong
Summary: This study retrospectively enrolled patients with lung adenocarcinomas harboring EGFR mutations who were treated with first-line afatinib. Patients who received local consolidative therapy (LCT) had significantly longer PFS and OS. Multivariable analysis and propensity score-weighting showed consistent results. This study suggests that LCT may improve clinical outcomes, in terms of PFS and OS, in patients with advanced EGFR-mutant lung adenocarcinomas who are treated with first-line afatinib.
Article
Oncology
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu
Summary: This retrospective analysis compared the efficacy of afatinib combined with bevacizumab to erlotinib combined with bevacizumab in the first-line treatment of EGFR-mutated NSCLC, showing no significant difference in objective response rate and disease control rate between the two combination therapies, with diarrhea being more common in the afatinib group.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Article
Oncology
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Summary: This study analyzed the outcomes of advanced EGFR-mutated non-small cell lung cancer patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs. The majority of resistance to first-line therapy was associated with the T790M mutation. Sequential osimertinib treatment in patients with positive secondary T790M mutation showed better outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Chieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, Chia-Hung Chen, Chih-Yen Tu, Te-Chun Hsia, Wen-Chien Cheng, Hung-Jen Chen
Summary: This retrospective observational study analyzed the survival outcomes of patients with resected stage III adenocarcinoma with EGFR mutations who received perioperative chemotherapy and EGFR-TKIs. The study found that perioperative EGFR-TKIs led to longer progression-free survival, while perioperative chemotherapy resulted in longer overall survival. Perioperative treatment with EGFR-TKIs was identified as an independent predictor of poor overall survival.
Article
Oncology
Jianlin Long, Shuangyi Lei, Zhijuan Wu, Shuanglong Xiong, Chunmei Wang, Lumi Huang, Guanzhong Liang, Dan Yang, Yan Teng, Yongsheng Li, Jun Qi, Dairong Li
Summary: This study assessed the efficacy and safety of the original EGFR-TKI combined with bevacizumab in metastatic EGFR-positive non-small cell lung cancer patients. The results showed that this combination treatment had a favorable effect in prolonging progression-free survival and was well tolerated.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Lingzhi Hong, Whitney E. Lewis, Monique Nilsson, Sonia Patel, Susan Varghese, Melvin J. Rivera, Robyn R. Du, Pingjun Chen, Haley N. Kemp, Waree Rinsurongkawong, Simon Heeke, Amy R. Spelman, Yasir Y. Elamin, Marcelo Negrao, Boris Sepesi, Don L. Gibbons, J. Jack Lee, Jia Wu, Natalie Vokes, John Heymach, Jianjun Zhang, Xiuning Le
Summary: The addition of anti-PD1 immunotherapy did not provide additional benefit to chemotherapy for EGFR-mutant LUAD patients with TKI resistance. However, there was a trend towards benefit with anti-VEGF therapy. The ideal choice for post-TKI treatment is still being evaluated.
Article
Pharmacology & Pharmacy
Yang Chen, Hanhan Hong, Shujun Bao, Hao Tang
Summary: This case report describes a patient with NSCLC and multiple EGFR mutations who developed SJS after sequential use of EGFR-TKIs and toripalimab. TKI treatment after SJS was well tolerated and effective.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Summary: A novel nomogram was created in this study to help physicians suggest the optimal treatment for EGFRm+ NSCLC patients. The nomogram was based on pretreatment factors and stratified patients into five different risk groups for progression-free survival (PFS) and overall survival (OS). This risk stratification can provide additional information for clinicians and patients in determining the optimal therapeutic options.
Review
Pharmacology & Pharmacy
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami, Amer E. Alkhalifa
Summary: Angiogenesis plays a vital role in the growth and spread of solid cancers, but breast cancer has shown poor response to anti-angiogenic drugs. Assessing the angiogenic signaling mechanisms in breast cancer, exploring new drug targets, and improving treatment outcomes through vascular normalization and nanotechnology are important areas of research.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Yuman Yu, Yuehong Wang, Linying Wu, Xuanli Xu, Hua Zhou, Qing Wang, Jianying Zhou
Summary: The study evaluated the efficacy of EGFR-TKIs plus bevacizumab in advanced non-squamous EGFR-mutated NSCLC patients with gradual progression, showing that the treatment was well-tolerated and promising. Patients with high baseline serum VEGF levels had better PFS2 than those with low baseline levels.
Article
Oncology
Nan Jin, Chunxiao Sun, Yijia Hua, Xinyu Wu, Wei Li, Yongmei Yin
Summary: We report the first case of significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs treated with anlotinib. This finding suggests a potential novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to surgically resect.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Jehun Kim, Tae Won Jang, Chang Min Choi, Mi Hyun Kim, Sung Yong Lee, Cheol Kyu Park, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Chan Kwon Park, Sang Hoon Lee, Seung Hun Jang, Seong Hoon Yoon
Summary: This study aimed to identify prognostic factors for brain metastases (BMs) in non-small cell lung cancer (NSCLC) patients and evaluate the treatment outcomes of first-line afatinib in patients with EGFR-mutant NSCLC and BM in a real-world setting. CNS failure was found to be a poor prognostic factor for time on treatment (TOT) and overall survival (OS), correlated with younger age, poor performance status, higher metastatic number, advanced disease, uncommon EGFR mutations, and baseline liver and/or bone metastases.
TRANSLATIONAL LUNG CANCER RESEARCH
(2023)
Article
Oncology
John Wen-Cheng Chang, Chen-Yang Huang, Yueh-Fu Fang, Ching-Fu Chang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, Chiao-En Wu
Summary: A novel nomogram was created in this study to help physicians suggest the optimal treatment for EGFRm+ NSCLC patients. The nomogram was based on pretreatment factors and stratified patients into five different risk groups for progression-free survival (PFS) and overall survival (OS). This risk stratification can provide additional information for clinicians and patients in determining the optimal therapeutic options.
Article
Oncology
Chih-Hsi Scott Kuo, Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Cheng-Ta Yang
Summary: This study, based on real-world data, suggests that bevacizumab treatment may have moderate efficacy in EGFR-mutant advanced non-small cell lung cancer patients receiving afatinib therapy.
Article
Oncology
Chiao-En Wu, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, John Wen-Cheng Chang
Summary: This study reviewed the clinical outcomes and safety of EGFR-TKI treatment in lung adenocarcinoma patients with poor performance status and identified independent prognostic factors. The results showed that patients treated with 40 mg afatinib had better survival outcomes and dose adjustment was an independent prognostic factor for both progression-free survival and overall survival. This study provided evidence and prognostic factors for the use of EGFR-TKIs in patients with poor performance status.
Article
Medicine, General & Internal
Ming-Ru Lin, Po-Jui Chang, Ping-Chih Hsu, Chun-Sui Lin, Cheng-Hsun Chiu, Chih-Jung Chen
Summary: In the care bundle for central venous catheters, 2% chlorhexidine gluconate-alcohol (CHG) is superior to 10% povidone-iodine-alcohol (PVI) in inhibiting skin flora growth at insertion sites and potentially reducing the incidence of catheter-related bloodstream infections (CRBSIs).
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Health Care Sciences & Services
Hsin-Hsien Li, Chih-Wei Wang, Chih-Hao Chang, Chung-Chi Huang, Han-Shui Hsu, Li-Chung Chiu
Summary: This study found that prompt action to prevent injurious mechanical stretching of lung tissue and subsequent fibrosis may have a positive impact on clinical outcomes.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Cell Biology
Shu-Er Chow, Yaa-Jyuhn J. Meir, Jhy-Ming Li, Ping-Chih Hsu, Cheng-Ta Yang
Summary: This study investigates the dynamic changes in nuclear p120 catenin localization during cell cycle progression, revealing its role in the formation of the chromosome periphery and its interaction with lumican. Furthermore, it validates the protective role of p120 catenin in maintaining chromosome integrity.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Ping-Chih Hsu, Jhy-Ming Li, Cheng-Ta Yang
Summary: The overexpression of STAT3 in human small cell lung cancer cells promotes epithelial-mesenchymal transition, invasion, and proliferation through the activation of the YAP signaling pathway.
Article
Biotechnology & Applied Microbiology
Satoru Miura, Hyun Ae Jung, Shin Yup Lee, Seung Hyeun Lee, Min Ki Lee, Yong Chul Lee, Maximilian J. Hochmair, Cheng-Ta Yang, Angela Marten, James Chih-Hsin Yang, Sanjay Popat
Summary: Sequential afatinib/osimertinib treatment showed promising activity in Asian patients with EGFR mutation-positive NSCLC, especially those with Del19-positive disease. This treatment was effective in real-world patients, including those with T790M-mediated acquired resistance and poor ECOG PS or brain metastases.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
Yan-Jei Tang, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Ping-Chih Hsu, Chiao-En Wu
Summary: This study confirmed the greater efficacy of later-line osimertinib for NSCLC with acquired T790M mutation than for NSCLC without acquired T790M mutation. Detection of the T790M mutation after frontline treatment is crucial for prolonging the survival of NSCLC patients. Osimertinib may be considered an option for NSCLC with unknown T790M mutations.
Article
Biochemistry & Molecular Biology
Li-Chung Chiu, Hsiang-Yu Tang, Chun-Ming Fan, Chi-Jen Lo, Han-Chung Hu, Kuo-Chin Kao, Mei-Ling Cheng
Summary: Acute respiratory distress syndrome (ARDS) is characterized by dysregulated immune-inflammatory responses and high mortality. This study found that the activation of the kynurenine pathway, a metabolic pathway, is associated with mortality in ARDS patients. Plasma kynurenine levels and the kynurenine/tryptophan ratio were higher in non-survivors compared to survivors. Urine metabolic profiling also revealed higher tryptophan degradation in non-survivors. These findings suggest that the kynurenine pathway could serve as a prognostic marker and a target for therapeutic interventions in ARDS.
Article
Medicine, General & Internal
Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Summary: Anti-PD-1/PD-L1 immune checkpoint inhibitors combined with bevacizumab and platinum-based chemotherapy have shown promising efficacy in treating metastatic non-squamous cell lung cancer. However, drug-induced nephrotoxicity is a rare but serious adverse effect that requires careful evaluation and management.
CLINICS AND PRACTICE
(2023)
Article
Respiratory System
Ping-Chih Hsu, John Wen-Cheng Chang, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Yueh-Fu Fang, Chiao-En Wu
Summary: This study analyzed the clinical outcomes of sequential therapy following first-line EGFR-TKIs and the predictive factors of an acquired T790M mutation. The results showed that osimertinib significantly improved the overall survival of NSCLC patients with T790M mutation.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2022)
Article
Medicine, General & Internal
Chung-Shu Lee, Li-Chung Chiu, Chih-Hao Chang, Fu-Tsai Chung, Shih-Hong Li, Chun-Liang Chou, Chih-Wei Wang, Shu-Min Lin
Summary: The mycobacterial culture from pleural tissue obtained by forceps biopsy through medical pleuroscopy is an effective method for diagnosing tuberculous pleurisy.
MEDICINA-LITHUANIA
(2022)
